Comparative Pharmacology
Head-to-head clinical analysis: HYDROXYCHLOROQUINE SULFATE versus LEFLUNOMIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDROXYCHLOROQUINE SULFATE versus LEFLUNOMIDE.
HYDROXYCHLOROQUINE SULFATE vs LEFLUNOMIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Antimalarial and immunosuppressive agent. Accumulates in lysosomes, raising pH, impairing antigen processing and presentation. Inhibits toll-like receptor signaling and cytokine production (e.g., IL-6, TNF-α). Interferes with quinone reductase activity and heme polymerization in plasmodia.
Inhibits dihydroorotate dehydrogenase (DHODH), blocking de novo pyrimidine synthesis, thereby reducing lymphocyte proliferation.
200-400 mg orally once daily or divided twice daily; maximum 600 mg/day or 6.5 mg/kg/day (whichever is lower). For malaria: 800 mg loading dose, then 400 mg at 6, 24, and 48 hours.
100 mg PO once daily for 3 days (loading dose), then 20 mg PO once daily (maintenance); may reduce to 10 mg PO once daily if not tolerated.
None Documented
None Documented
Clinical Note
moderateLeflunomide + Digitoxin
"Leflunomide may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateLeflunomide + Deslanoside
"Leflunomide may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateLeflunomide + Acetyldigitoxin
"Leflunomide may decrease the cardiotoxic activities of Acetyldigitoxin."
Clinical Note
moderateLeflunomide + Ouabain
"Leflunomide may decrease the cardiotoxic activities of Ouabain."
Terminal half-life: ~40–50 days (range 30–60 days) due to extensive tissue distribution. Steady-state reached after 4–6 months.
Terminal half-life of teriflunomide is approximately 18-19 days (range 14-58 days) due to enterohepatic recirculation; clinical significance: prolonged washout required before switching to other disease-modifying antirheumatic drugs (DMARDs) or in case of toxicity.
Renal: ~50% unchanged; Hepatic metabolism: ~50% (desethylchloroquine, desethylhydroxychloroquine); Fecal: minimal (<5%).
Primarily fecal (~48%) and renal (~43%) as metabolites. Teriflunomide, the active metabolite, undergoes enterohepatic recirculation and is eliminated via bile and feces. Less than 1% excreted as unchanged drug.
Category A/B
Category D/X
Antimalarial / DMARD
DMARD